Watson helper post on ymb this morning regarding M
Post# of 30070
Posted On: 08/23/2014 10:47:08 AM
Watson helper post on ymb this morning regarding MANF and ischemia. The possible applications for MANF are truly astonishing. Can you imagine if a bidding war breaks out to outright buy AMBS....Oh my! Sorry just dreaming, I don't think the BOD or BOA were ever sell, but can you imagine?
Protected against death induced by Ischemia Jun 27th
.
Not sure if this showed up, I have a file with records on MANF and didn't see a publication. This is around stroke, some technical and some fairly understood by regular investors:
The recombinant human MANF was therapeutically administrated to the ipsilateral ventricle at 2h after MCAO. MANF decreased the number of the propidium iodide (PI)- and TUNEL-positive neural cells. Contrarily, MANF protected the NeuN-positive cells in hippocampus and cortex from death induced by ischemia. The more interesting results in this study were that MANF repressed the cleavage of caspase-3 triggered by focal cerebral ischemia. MANF also reduced the elevated levels of BIP/Grp78, phosphorylated IRE1, and splicing XBP1 induced by focal cerebral ischemia, but not affect CHOP expression. Meanwhile, focal cerebral ischemia elevated the levels of XBP1 mRNA, including unspliced XBP1 (XBP1u) and spliced XBP1 (XBP1s). However, MANF did not affect the expression of XBP1 mRNA, neither XBP1u nor XBP1s. These results suggest that MANF can prevent the neuron loss via inhibiting ischemia-induced apoptosis and regulating unfolded protein response-related genes.
Important for a key reason, FDA will approve. I have just received three notices on drugs passing ORD IND approval process to start 1/2 or phase 1 trials. You'll see some disclosures filed soon. Wolframs, probably Type 1 will be included due to high mortality rate in certain patients
Protected against death induced by Ischemia Jun 27th
.
Not sure if this showed up, I have a file with records on MANF and didn't see a publication. This is around stroke, some technical and some fairly understood by regular investors:
The recombinant human MANF was therapeutically administrated to the ipsilateral ventricle at 2h after MCAO. MANF decreased the number of the propidium iodide (PI)- and TUNEL-positive neural cells. Contrarily, MANF protected the NeuN-positive cells in hippocampus and cortex from death induced by ischemia. The more interesting results in this study were that MANF repressed the cleavage of caspase-3 triggered by focal cerebral ischemia. MANF also reduced the elevated levels of BIP/Grp78, phosphorylated IRE1, and splicing XBP1 induced by focal cerebral ischemia, but not affect CHOP expression. Meanwhile, focal cerebral ischemia elevated the levels of XBP1 mRNA, including unspliced XBP1 (XBP1u) and spliced XBP1 (XBP1s). However, MANF did not affect the expression of XBP1 mRNA, neither XBP1u nor XBP1s. These results suggest that MANF can prevent the neuron loss via inhibiting ischemia-induced apoptosis and regulating unfolded protein response-related genes.
Important for a key reason, FDA will approve. I have just received three notices on drugs passing ORD IND approval process to start 1/2 or phase 1 trials. You'll see some disclosures filed soon. Wolframs, probably Type 1 will be included due to high mortality rate in certain patients
(0)
(0)